Terconazole
- CAS Codes:67915-31-5
- PHARMGKB ID:67915-31-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Terazol, Terconazole; USA: Terazol, Terconazole.
Latin America
Brazil: Gyno-Fungix, Tecomax; Mexico: Fungistat-Janssen.
Drug combinations
Chemistry
Terconazole: C~26~H~31~Cl~2~N~5~O~3~. Mw: 532.46. (1) Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis-; (2) cis-1-[p-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine. CAS-67915-31-5 (1980).
Pharmacologic Category
Skin and Mucous Membrane Agents; Antifungals; Azoles. Vaginal Antifungal Agent.
Mechanism of action
Triazole ketal antifungal agent. Involves inhibition of fungal cytochrome P450. Specifically, terconazole inhibits cytochrome P450-dependent 14-α-demethylase which results in accumulation of membrane disturbing 14-α-demethylsterols and ergosterol depletion.
Therapeutic use
Local treatment of vulvovaginal candidiasis.
Pregnancy and lactiation implications
Use with caution in pregnancy. Not recommended in lactation (excretion in breast milk unknown).
Unlabeled use
Contraindications
Hypersensitivity to terconazole or any component of the formulation.
Warnings and precautions
Irritation or sensitization might occur. Petrolatum-based vaginal products may damage rubber or latex condoms or diaphragms.